Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718411 | 0.92 | HTR2A (0.50) | HTR2AHTR2CPARP1ABCB1HRH1 | |
| SCHEMBL6715280 | 0.90 | HTR2A (0.56) | HTR2AHTR2CPARP1 | |
| SCHEMBL6715392 | 0.76 | HTR2A (0.59) | HTR2AHTR2CPARP1 | |
| SCHEMBL6713804 | 0.76 | HTR2A (0.56) | HTR2AHTR2CPARP1HRH4 | |
| SCHEMBL6713706 | 0.75 | HTR2A (0.58) | HTR2AHTR2CPARP1 | |
| SCHEMBL6714438 | 0.75 | HTR2C (0.52) | HTR2AHTR2CPARP1 | |
| SCHEMBL6711108 | 0.73 | HTR2A (0.62) | HTR2AHTR2CPARP1 | |
| SCHEMBL6710943 | 0.73 | HTR2A (0.52) | HTR2AHTR2CPARP1 | |
| SCHEMBL6718939 | 0.73 | HTR2A (0.52) | HTR2AHTR2CPARP1 | |
| SCHEMBL6711057 | 0.73 | HTR2A (0.49) | HTR2AHTR2CPARP1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | PHARMACIA & UPJOHN COMPANY | 2002-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HTR1D, HTR1A, HTR1E | HTR2A 18/4885HTR2C 7/4885PARP1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.